Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

John N. Allan, Daniel Helbig, Erin Mulvey, Sarah Nazir, Sandra Stewart, Melissa L. Lapinta, Sarah C. Rutherford, Jia Ruan, John P. Leonard, Peter Martin, Richard R. Furman

Blood (2023) 142 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2023-174465

Published: 2023

Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 497.

https://doi.org/10.1182/blood-2023-182114

Published: 2023

Journal Articles

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

Jennifer L. Crombie, Matthew Matasar, Max S. Topp, John N. Allan, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jessica Cai, Dina M. Flink, Min Zhu, Jurriaan Brouwer-Visser, Hesham Mohamed, Aafia Chaudhry, Srikanth Ambati, Steve M Ansell

Blood (2023) 142 (Supplement 1): 4461.

https://doi.org/10.1182/blood-2023-181602

Published: 2023

Journal Articles

The Characterization of Metabolic Profile and Substrates Dependencies of Richter's Syndrome Cells Open for Translational Opportunities

Matilde Micillo, Lorenzo Brandimarte, Giulia Omezzolli, Nadia Bertola, Francesco Edoardo Vallone, Andrea Iannello, Chiara Lavarello, Nicole Grinovero, Giulio Ferrero, Kevin Mellert, Peter Moller, Nicoletta Vitale, Silvia Bruno, Richard R. Furman, John N. Allan, Andrea Petretto, Silvia Deaglio, Silvia Ravera, Tiziana Vaisitti

Blood (2023) 142 (Supplement 1): 6115.

https://doi.org/10.1182/blood-2023-179164

Published: 2023

Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 633.

https://doi.org/10.1182/blood-2023-187128

Published: 2023

Journal Articles

Overall Survival Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients with High-Risk Molecular-Cytogenetic Features Treated with 1L Ibrutinib: A Comparative Effectiveness Study Using the Flatiron Health Data

John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P Qureshi, Susan M. O'Brien

Blood (2023) 142 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2023-184318

Published: 2023

Journal Articles

A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

John N. Allan, Adam S Kittai, Dan James, Helen Ridge, Miguel Miranda, Alan Yong, Fady Fam, Jack Roos, Vikram Shetty, Matthew S. Davids, Alan Skarbnik

Blood (2023) 142 (Supplement 1): 6563.

https://doi.org/10.1182/blood-2023-178698

Published: 2023

Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 224–227.

https://doi.org/10.1182/blood-2022-160338

Published: 2022

Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin

Blood (2022) 140 (Supplement 1): 175–177.

https://doi.org/10.1182/blood-2022-158656

Published: 2022

Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Blood (2022) 139 (22): 3278–3289.

https://doi.org/10.1182/blood.2021014488

Published: 2022

Includes: Supplemental data

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Blood (2021) 138 (Supplement 1): 2628.

https://doi.org/10.1182/blood-2021-150751

Published: 2021

Journal Articles

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

Francesca Arruga, Andrea Iannello, Nikolaos Ioannou, Alberto Maria Todesco, Marta Coscia, Riccardo Moia, Gianluca Gaidano, John N. Allan, Richard Furman, Tiziana Vaisitti, Alan G. Ramsay, Silvia Deaglio

Blood (2021) 138 (Supplement 1): 3718.

https://doi.org/10.1182/blood-2021-150183

Published: 2021

Journal Articles

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander R. Coltoff, Matthew S. Davids, Peter O. Baker, Lori Leslie, Kerry A. Rogers, John N. Allan, Raul Cordoba, Alberto Lopez-Garcia, Darko Antic, John M. Pagel, Nicolas Martinez-Calle, José Antonio García-Marco, Jose‐Ángel Hernández‐Rivas, Fatima Miras, Catherine C. Coombs, Anders Österborg, Lotta Hansson, Amanda N. Seddon, Javier López Jiménez, Matthew R. Wilson, Dima El-Sharkawi, Daniel Wojenski, Shuo Ma, Talha Munir, Susana Valenciano, Erlene Seymour, Paul M. Barr, Jeffrey Pu, Piers E. M. Patten, Guilherme F. Perini, Scott F. Huntington, Helen Parry, Suchitra Sundaram, Alan Skarbnik, Manali Kamdar, Ryan Jacobs, Harriet Walter, Renata Walewska, Angus Broom, Sonia Lebowitz, Krista M. Isaac, Craig A. Portell, Inhye E. Ahn, Chaitra S. Ujjani, Mazyar Shadman, Sigrid S. Skånland, Elise A. Chong, Anthony R. Mato

Blood (2021) 138 (18): 1768–1773.

https://doi.org/10.1182/blood.2021011841

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. Miller, Brian J. Lannutti, Richard R. Furman, Katti A. Jessen, Silvia Deaglio

Blood (2021) 137 (24): 3365–3377.

https://doi.org/10.1182/blood.2020008404

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Blood (2020) 136 (Supplement 1): 19–22.

https://doi.org/10.1182/blood-2020-134676

Published: 2020

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134699

Published: 2020

Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134431

Published: 2020

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Samuel Yamshon, MD, Peter Martin, FRCPC, MD MS, Bijal Shah, MD, Stephen J. Schuster, MD, Paul J Christos, Dr.P.H., M.S., Amelyn Rodriguez, BSN, RN, OCN, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Sarah C. Rutherford, MD, John N. Allan, MD, John P. Leonard, MD, Jia Ruan, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-138731

Published: 2020

NARROW

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

The Characterization of Metabolic Profile and Substrates Dependencies of Richter's Syndrome Cells Open for Translational Opportunities

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Overall Survival Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients with High-Risk Molecular-Cytogenetic Features Treated with 1L Ibrutinib: A Comparative Effectiveness Study Using the Flatiron Health Data

A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only